Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Stopped The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.

Conditions

• Solid Tumor
• Hematological Malignancy

Interventions

• DRUG: ATG-017
• DRUG: ATG-017+Nivolumab

Sponsor

Antengene Therapeutics Limited

Collaborators

• [object Object]